Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

August 7, 2025

NASDAQ US Health Care Biotechnology earnings 28 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thanks a lot, operator, and good afternoon to all of you. We appreciate you being here for Corvus Pharmaceuticals' Second Quarter 2025 Business Update and Financial Results Conference Call; joining us to go over the results and business updates are Richard Miller, our Chief Executive Officer; Leiv Lea, our Chief Financial Officer; Jeffrey Arcara, our Chief Business Officer; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. Our executive team will kick things off with some prepared remarks, and after that we'll move into a question-and-answer period. I want to remind everybody that what management says today, along with responses to questions, will contain forward-looking statements. Such forward-looking statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' quarterly report on Form 10-Q for the quarter ended June 30, 2025, and other filings the company makes with the SEC from time to time. Except as required by law, the company assumes no obligation to publicly update or revise any forward-looking statements. With that said, I'd like to hand the call over to Leiv Lea. Leiv?

Leiv Lea

executive
#2

Thanks, Zack. I'll start by giving a quick rundown of how our finances looked in the second quarter of 2025, and after that I'll hand things over to Richard for an update on the business. R&D expenses for the second quarter of 2025 came to $7.9 million, versus $4.1 million during the comparable period in 2024. That $3.8 million rise stemmed mainly from greater clinical trial and manufacturing costs tied to developing soquelitinib, along with higher personnel-related costs. We posted a net loss of $8 million in the second quarter of 2025, which included a noncash loss of $400,000 tied to Angel Pharmaceuticals, our partner in China. On top of that, during the second quarter of 2025 we recorded a noncash gain of $2 million from the change in fair value of Corvus' warrant liability. That compares with a net loss of $4.3 million during the same period in 2024, which had included a $1.8 million noncash gain tied to the change in fair value of Corvus' warrant liability and a $600,000 noncash loss tied to Angel Pharmaceuticals. Total stock compensation expense for the second quarter 2025 came in at $1.3 million, versus $800,000 during the same period in 2024. As of June 30, 2025, Corvus held cash, cash equivalents and marketable securities amounting to $74.4 million, compared with $52 million at December 31, 2024. During the second quarter, every one of the remaining common stock warrants was exercised, generating cash proceeds of roughly $35.7 million, which included $2 million from warrants exercised by our CEO, Dr. Miller. Given our current plans, we expect the cash we have now to fund operations into the fourth quarter of 2026. I'll now hand the call over to Richard, who will walk through our clinical progress and go into more detail on our strategy and plans.

Richard Miller

executive
#3

Thanks, Leiv, and good afternoon to all of you. We appreciate your joining today's update call. Developing soquelitinib for atopic dermatitis remains our primary focus, and we think our position there is unique: an oral drug with a novel mechanism of action that has thus far demonstrated a favorable safety and efficacy profile; we're advancing significantly on many fronts, among them fresh data from our Phase I trial that was reported in June, which boosts our confidence in the long-term potential for soquelitinib in this indication and beyond. During today's call, I'll give a high-level recap of those data, go over our go-forward clinical plans, including the design of our planned Phase II trial, and touch briefly on progress with our other clinical programs. We see the data through Cohort 3 of the Phase I trial as very encouraging. Every treatment cohort showed a favorable safety and efficacy profile relative to placebo, and Cohort 3's data is especially exciting, showing responses that came earlier, ran deeper, and lasted longer than those in Cohorts 1 and 2. To be specific, after only 4 weeks of treatment, Cohort 3 demonstrated a mean percent reduction in EASI score of 64.8% versus 54.6% for the combined Cohorts 1 and 2 and 34.4% for placebo. Not a single placebo patient reached the clinically meaningful endpoints of EASI-75, EASI-90 or IGA 0 or 1. We contrast that with what was seen among soquelitinib patients, many of whom did reach these endpoints. In Cohort 3, 50% of patients reached EASI-75, 8% reached EASI-90, and 25% reached IGA 0 or 1. That compares with 29%, 4% and 21%, respectively, in the combined cohorts 1 and 2 that were treated. As for the kinetics of response, Cohort 3 showed earlier and deeper separation from placebo starting at day 8, with EASI score improvement continuing through day 15 and 28 and far beyond; among Cohorts 1 and 2, separation from placebo started at day 15 and continued to show separation at day 28. Across all 3 cohorts, this separation held up during the 30-day post-treatment follow-up period; furthermore, for all 3 cohorts, the downward slope of the curves from day 15 to day 28 hints that a longer treatment duration might deepen responses even more. We've also found a remarkable impact on PP-NRS, a patient self-reported assessment of itch. Several Cohort 3 patients reported steep drops in the score starting at day 8, which lined up with the reductions we observe in serum cytokine levels of IL-31 and IL-33. Both of these cytokines are known to play a role in the itch response; beyond that, other biomarker data from the trial continues to support the ITK inhibition mechanism of action, including the potential induction of anti-inflammatory T regulatory cells. On safety, no safety issues were observed with soquelitinib, with no significant differences between the treatment and placebo groups, and no clinically significant laboratory abnormalities were seen. So at this point, more than 150 individuals with either T-cell lymphoma or atopic dermatitis have received soquelitinib as part of our overall clinical experience, which adds up to over 9,000 days of patient treatment; within the lymphoma study, certain patients have remained on daily therapy continuously for as long as 2 years. Given what we've seen so far, we're moving soquelitinib forward in clinical development along 2 paths. The first: we changed the Phase I protocol so that the previously planned Cohort 4 is replaced by an extension Cohort 4, which is going to look at 24 more patients receiving the Cohort 3 dose, 200 milligrams twice per day, administered over 8 weeks, followed by an extra 30 days of follow-up with no therapy. Those 24 patients will be assigned randomly, in a blinded 1:1 fashion, against placebo — 12 on active drug and 12 on placebo. From this extension Cohort 4, we'll get data covering a longer duration of treatment, 8 weeks rather than the 4 weeks observed in Cohorts 1 and 3; we've already enrolled over half of the patients, and we still expect that data from the extension cohort will be ready in the fourth quarter. The second path: we're putting the finishing touches on the design for our planned Phase II trial of soquelitinib in atopic dermatitis, and I'm glad to walk you through those plans right now. This will be an international, randomized, placebo-controlled, double-blinded trial. The company will be blinded as well. Around 200 patients with moderate to severe atopic dermatitis who have failed at least one prior topical or systemic therapy will be enrolled. To qualify, patients need a baseline EASI score greater than or equal to 16, an IGA of 3 or 4, and body surface involvement greater than or equal to 10%. Randomization will divide patients equally across 4 cohorts, with 50 patients per cohort, each receiving 200-milligram soquelitinib once per day, 200 milligrams twice per day, 400 milligrams once per day, or placebo. Let me run through those groups again: 200 milligrams once per day, 200 milligrams twice per day, 400 milligrams once per day, or placebo. Treatment will last 12 weeks, and afterward patients will be followed for another 30 days off therapy. The primary endpoint is the percent change in EASI score from baseline to week 12. Secondary endpoints will cover the percent of patients achieving EASI-75 or IGA 0 or 1 at week 12. Itch impact will be assessed through the percent of patients reaching a decrease of greater than or equal to 4 points on the PP-NRS scale at week 12, along with safety, naturally. We expect to include 30 to 40 clinical trial sites around the world; right now we're finalizing the trial design together with the investigators, with strong interest coming from many leading centers, and we remain on track to launch the trial before the year ends. Beyond our own clinical trials, our partner in China, Angel Pharmaceuticals, intends to launch a Phase Ib/II trial of soquelitinib for atopic dermatitis in China. A total of 48 patients are going to be enrolled in this study, and we expect it to expand upon what we learned in our Phase I trial. That means evaluating a longer duration of treatment — 12 weeks — plus another dosing choice, 400 milligrams taken once per day, which matches where our Phase II trial is heading. A quick update on our remaining clinical efforts: an abstract has been submitted so we can share the final data from our Phase I study of soquelitinib in relapsed/refractory T-cell lymphomas this December at the American Society of Hematology gathering. Enrollment is still open for our registrational Phase III study of soquelitinib among relapsed PTCL patients, as we work toward interim data in late 2026. On top of that, we are still signing up participants for our Phase II study of soquelitinib in people who have ALPS, or autoimmune lymphoproliferative syndrome. Whether we might observe preliminary findings from that Phase II ALPS study in late 2025 or early 2026 depends on how enrollment goes. Sign-ups have finished for our Phase II study of ciforadenant in renal cell cancer. An oral presentation in October at the ESMO meeting, the European Society for Medical Oncology, will feature those results. To wrap up, the findings for soquelitinib in atopic dermatitis and T-cell lymphoma highlight how important ITK is as a key target across a variety of illnesses tied to inflammation and cancer, and they show the wide-ranging promise of soquelitinib throughout many fields of medicine, including dermatology, oncology, rheumatology, pulmonary medicine and beyond. It feels like we might be at the start of a new chapter in immunotherapy for autoimmune inflammatory conditions — one built on medicines with innovative ways of working that adjust or restore immune balance by holding pro-inflammatory or abnormal T cells in check. That possibility is what pushed us to pair soquelitinib's development with efforts to discover and create next-generation ITK inhibitors possessing distinctive characteristics. Looking ahead to the near term, we're eager to keep advancing soquelitinib's clinical development in atopic dermatitis and PTCL, and to give updates on our programs over the next few quarters. At this point I'll hand the call to the operator for a questions-and-answer session. Operator?

Jeff Jones

analyst
#4

Congratulations on such an extremely productive quarter. I suppose there are a great many opportunities sitting right in front of you. When you consider Cifo for autoimmune disease, beyond speeding things up the way you're doing in Phase II, what's your thinking regarding additional indications, and how do you plan financially to back all the many possibilities that Cifo stands for?

Richard Miller

executive
#5

All right; Jeff, allow me to start with a correction. That's right, Cifo is renal cell cancer; however, soquelitinib, clearly, we are going after atopic dermatitis quite aggressively, though we've already started considering what comes after. And regarding the 2 indications we have in mind, we're considering 2 of them. The first, naturally, would — we kind of wish to keep our footprint in dermatology. We've got experience in that space at this point. We possess a great deal of knowledge about, in our view, how the drug behaves in these cutaneous diseases. So a probable target for us could be something along the lines of hidradenitis suppurativa. The unmet need there is absolute, I'd say. And then the second disease, shifting away from dermatology into the inflammation space, would be pulmonary disease. Asthma is likely the condition with the strongest scientific rationale — probably asthma; we have 3 or 4 distinct animal models in which we observe outstanding activity from our drug against asthma, both acute and chronic. On top of that, the mechanism of action, in particular the inhibition of what's known as innate lymphoid cells, genuinely makes us think we could have a highly significant novel approach for asthma and maybe other pulmonary diseases. Still, you're absolutely right. We — pursuing every one of these indications is hard for us. Yet we've demonstrated that we're extremely capable and nimble when it comes to efficiently extracting maximum value from, I'd say, every one of our products.

Jeff Jones

analyst
#6

Thanks for that. My next question concerns Cifo. Regarding the kidney data that will be presented at ESMO, what's your view on where the program goes next, if we assume an oral presentation will show a favorable result for it?

Leiv Lea

executive
#7

All right. Let me start by reminding everybody that ciforadenant is an oral A2A antagonist. We ran a Phase II trial in first-line renal cell cancer with patients on ipi + nivo. We then added the A2A antagonist, and the goal, obviously, was to examine response rate, but equally important, to examine the fact that these patients take the A2A antagonist daily over a long period, while ipi + nivo is given only briefly. Beyond objective responses, I believe one thing we'll be watching for is how long responses last, along with PFS. So we'll wait and see what that data shows. The Kidney Cancer Consortium conducted this study across multiple centers, including MD Anderson, Vanderbilt and others. They carried out the trial, while we supplied the drug plus some financial backing. So let's see what gets presented in an oral session at ESMO, and we'll proceed from there. Depending on what the data shows, we'll decide how to move forward with it.

Richard Miller

executive
#8

Alright. That said, this trial is fairly unusual. What I mean is, it involves first-line disease. The cancer is renal cell. We're aware that this type is responsive to immune therapy. The reason I'm stressing this is that I know another company released some A2A data today, and if I recall correctly, it concerned metastatic colon cancer, and they were dealing with chemotherapy along with a range of other treatments. One area where we've consistently performed well involves first studying our agents as monotherapy in a careful way, then progressing to combinations once we have solid insight into efficacy, safety, and mechanism; that approach has served us greatly. Is that a satisfactory response to what you asked?

Jeff Jones

analyst
#9

That's right.

Analyst

analyst
#10

Sam here, filling in for Graig. Nice work on the advances. Perhaps a fast question regarding soquelitinib and PTCL. I'm just wondering how the enrollment is progressing and whether the earlier guidance for data in late 2026 still holds.

Richard Miller

executive
#11

That guidance remains unchanged. Enrollment is proceeding as we planned; at this point we have roughly 20 sites up and running. These rank among the finest centers across the United States and Canada. So all of that is moving forward as expected. And it's our hope that the Phase I presentation will truly begin to draw attention to this drug.

Aydin Huseynov

analyst
#12

Great results this quarter. A handful of things we'd like to ask about; can you walk us through the reasoning that shaped the Phase II trial design in atopic dermatitis? The specifics you gave on the four cohorts are helpful — 200 Q.D., 200 B.I.D., 400 Q.D., and placebo. Based on what's emerged in atopic dermatitis so far, Cohort 3 has delivered the biggest response. So I'm curious whether this came largely from an FDA recommendation to add a somewhat lower dose and a somewhat — a somewhat higher dose? If you could just take us through how that unfolded.

Richard Miller

executive
#13

All right. I appreciate the question. To kick things off, when it comes to Phase II studies in atopic dermatitis, there's no shortage of examples these days. Other companies have already gone down this road before us. A trial enrolling 200 patients, roughly 50 per arm, is what I would call pretty much the norm. And Aydin, you're correct. Usually the FDA is looking for a range of doses to be explored, which lets you determine the lowest dose that might work as well as a higher dose that perhaps delivers no added benefit over another. The reason those particular doses were selected is that we're confident the 200 milligram once-daily dose is active. We don't think it will turn out otherwise — and we've already put it through testing. Cohort 2 gave you those results. My view is that dose will end up being an active one. It's administered once per day. Naturally, a number of patients like the convenience of one dose daily when treating atopic dermatitis. That said, when we moved to 200 B.I.D., the response improved; in Cohort 3 we essentially doubled the amount, and that's the regimen under investigation in our extension study right now. So the second cohort consists of 200 given once daily and 200 given twice daily; beyond that, we obviously intend to test 400 once a day, which matches the total exposure of 200 B.I.D. while being taken only one time per day. My belief is that once-daily administration is feasible. This study should therefore let us verify that. Plus, naturally, there's the placebo component. The value of including placebos during Phase I and Phase II research cannot be overstated in my view. These days I notice firms running such trials without any placebo at all, which truly baffles me; regardless, this means 200 participants overall, split into two groups of 50 per arm, with placebo control and full blinding, including blinding of the company. The endpoints being used are quite conventional. For a Phase II trial, the typical primary measure is the average percentage shift in EASI, while the secondary measures consist of EASI-75 along with IGA-0 and IGA-1. So everything there is fairly standard. Right, and we're extending treatment to 12 weeks. We will already have data from 8 weeks of therapy, which is something we possess at this moment. We believe that ought to produce a fairly strong outcome. Turning to the statistical dimension, imagine we observe a 20% improvement in just one of those arms — pick whichever single arm you like and set it against placebo. Should we end up at 20% or 22% better, we anticipate exceeding that, even if there's a chance we finish at the lower bound of our model. At 80% power, a p-value of 0.05 would let us pick that up. For the Phase II trial, that's adequate. Thus, statistically speaking, the sample sizes make sense. Based on what we know, along with our grasp of receptor occupancy, the dosing makes sense as well. We view this as a highly manageable study for us. Corvus has substantial experience running these international Phase IIs, and 200 patients would be quite manageable for a company of that kind. Hopefully that addresses your question.

Aydin Huseynov

analyst
#14

Absolutely, it does. I just had a few follow-ups regarding this trial. I realize it may be somewhat early, but could you share the time line — when do you expect we might see results? I understand it's a randomized blinded study, but any hints about when it could be available would help.

Richard Miller

executive
#15

Okay, glad to provide that. Naturally, we've been considering it. Enrollment should take 12 to 15 months, results perhaps at 18 months, and the trial begins in December; I believe a few factors work in our favor. Clearly, it's oral, which ought to aid enrollment. Second, a novel mechanism of action should also make enrollment easier. Biopsies aren't required, though at some centers we'll try to encourage people to undergo them. That too ought to boost enrollment. Yet the main factor helping enrollment is that we permit patients who've failed systemic therapies. That truly widens the possible patient population. In many such studies, you're excluded if you've already failed a systemic therapy — a JAK inhibitor, say, or a dupi or similar, or an anti-IL-13 — but such patients are allowed here. We allow them because, first, our mechanism of action differs completely from those; and second, we've already had such patients in our study, and it made no difference — they've fared equally well.

Aydin Huseynov

analyst
#16

My guess, then, is that stratification will likely hinge on the specific therapy that didn't work for them—whether topical or systemic—correct?

Richard Miller

executive
#17

Definitely. What I mean is, you could stratify on a few different things. Clearly, EA—well, your baseline EASI score is going to serve as a stratification factor, along with whether the systemic therapy failed. Right. That level of specifics hasn't been worked out on our end as of yet, though there will likely be 2 or 3 separate stratification factors. With just 200 patients in a study, you can't have too many.

Aydin Huseynov

analyst
#18

Right, right. Yes. And what I wanted to ask about was the next-generation ITK inhibitor. As that program advances, might you share your thinking on the ways it will set itself apart from soquelitinib, and if it isn't too soon, which indications you would intend to go after?

Richard Miller

executive
#19

Okay. So before anything else, because of particular intellectual property considerations, I would prefer not to discuss specifics regarding what makes them different, since quite a few people are now pursuing ITK inhibitors. And I would prefer not to discuss specifics. But it's enough to say, allow me to respond to your question in this manner. ITK has many functions inside a cell, T cell receptor signaling, spanning everything from T cell receptor signaling through regulation of Th2 cytokine production all the way to apoptosis; and our belief is that we hold compounds which may perform better for certain of those indications than others, or for certain of those mechanisms. So allow me to respond in that manner.

Richard Miller

executive
#20

Thanks, operator. To start, I want to express my appreciation to all of you for joining us on this call. I’m eager to share another update with you next quarter and to bring you up to speed on how things are going across each of our clinical trials. Many thanks.

Operator

operator
#21

Everyone, that wraps up the call for today. We appreciate your joining us. You're free to leave the line now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.